Furosemide chemical structure
Find information on thousands of medical conditions and prescription drugs.

Lasix

Furosemide (INN) or frusemide (former BAN) is a loop diuretic used in the treatment of congestive heart failure and edema. It is most commonly marketed by Aventis Pharma under the brand name Lasix. It has also been used to prevent thoroughbred race horses from bleeding through the nose during races. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Along with some other diuretics, furosemide is also included on the World Anti-Doping Agency's banned drug list due to its alleged use as a masking agent for other drugs.

Mechanism of action

Like other loop diuretics, furosemide acts by inhibiting the Na/K/Cl cotransporter in the ascending loop of Henle. It also has inhibitory activity on carbonic anhydrase.

Clinical use in humans

Furosemide, as a loop diuretic, is principally used in the following indications (Aventis, 1998):

  • Edema associated with heart failure, hepatic cirrhosis, renal impairment, nephrotic syndrome
  • Hypertension
  • Adjunct in cerebral/pulmonary oedema where rapid diuresis is required (IV injection)

It is also sometimes used in the management of severe hypercalcemia in combination with adequate rehydration (Rossi, 2004).

It is considered ototoxic. (PMID 15311369)

Use in horses

Apparently, sometime in the early 1970s, furosemide's ability to prevent or at least greatly reduce the incidence of bleeding by horses during races was discovered accidentally. Pursuant to the racing rules of most states, horses that bleed from the nostrils three times are permanently barred from racing (for their own protection). Clinical trials followed, and by decade's end, racing commissions in some states began legalizing its use on race horses. On September 1, 1995, New York became the last state in the United States to approve such use, after years of refusing to consider doing so. Some states allow its use for all racehorses; some allow it only for confirmed "bleeders." Its use for this purpose is still prohibited in many other countries, however.

Brand names

Some of the brand names under which furosemide is marketed include: Aisemide®; Beronald®; Desdemin®; Discoid®; Diural®; Diurapid®; Dryptal®; Durafurid®; Errolon®; Eutensin®; Frusetic®; Frusid®; Fulsix®; Fuluvamide®; Furesis®; Furo-Puren®; Furosedon®; Hydro-rapid®; Impugan®; Katlex®; Lasilix®; Lasix®; Lowpston®; Macasirool®; Mirfat®; Nicorol®; Odemase®; Oedemex®; Profemin®; Rosemide®; Rusyde®; Trofurit®; Urex®

Read more at Wikipedia.org


[List your site here Free!]


Pulmonary edema after granulocyte-colony stimulating factor treatment in a bone marrow donor
From CHEST, 10/1/05 by Courtney S. Lucado

INTRODUCTION: We report a case of non-cardiogenic pulmonary edema following granulocyte-colony stimulating factor (G-CSF) administration in a bone marrow donor. During leukapheresis the patient was asymptomatic, but the next day she developed dyspnea, hypoxia, and bilateral pleural effusions. The patient clinically improved with diuretic and steroid therapy. We propose the significant leukocytosis triggered an inflammatory response leading to acute lung injury.

CASE PRESENTATION: A 21 year old white female at 28 weeks gestation had G-CSF administration for bone marrow donation for her sister. She was healthy and her pregnancy had been unremarkable. Her only medications were prenatal vitamins and iron. She received G-CSF 900 [micro]g (10 [micro]g/kg/day) intravenous daily for three days via a #12 French catheter in the internal jugular vein. On day four, the WBC peaked at 40.0 10[e.sup.9]/L and the patient underwent leukapheresis. The next morning, the catheter was removed taking care to avoid air embolism. Minutes later while walking to her car the patient developed shortness of breath and cough. She denied any associated chest pain. She had a presyncopal episode and was taken to the emergency room. She was hypoxic with arterial oxygen tension of 88 mmHg on 100% fractional inspired oxygen via nonrebreather mask. On examination she was normotensive, alert and oriented, with diffuse bilateral rales. Laboratory data showed normal kidney and liver function. WBC had decreased to 33.0 10[e.sup.9]/L. Hemoglobin was 12.6 g/dL. Platelets were at a nadir of 83 10[e.sup.9]/L following apheresis. A CT angiogram performed immediately on arrival to emergency room showed bilateral pleural effusions without evidence of clot or air embolism. Echocardiogram showed normal systolic function. Serial cardiac enzymes and electrocardiogram were normal. The patient received lasix and methylprednisone 40 mg intravenous every 12 hours. After several days she had normal oxygen saturation on room air. Methylprednisone was stopped and the patient was discharged home.

DISCUSSIONS: Pulmonary edema has been reported in patients receiving G-CSF. Capillary leak sydrome has been described in bone marrow recipients pretreated with G-CSF and is thought to be due to leukocyte activation with recruitment of inflammatory mediators leading to systemic inflammation and increased capillary permeability. Acute lung injury in bone marrow donors pretreated with G-CSF has been associated with increased levels of interleukin-1 beta as in the case described by Arimura et al. We are not aware of any reported cases of non-cardiogenic pulmonary edema after G-CSF in pregnant donors. The differential diagnosis also included embolic phenomenon. Air embolism was ruled out by CT, but remains a diagnosite consideration in the appropriate clinical setting. Air embolism causes the formation of platelet-fibrin aggregates and microthrombi leading to pulmonary hypertension and ultimately capillary leak. Although G-CSF and air embolism can both result in capillary, leak, the treament is very different for each of these conditions depending on the underlying mechanism.

CONCLUSION: In this case, marked leukocytosis following G-CSF mobilization of peripheral blood progenitor cells may have triggered the activation of inflammatory mediators in the lung resulting in noncardiogenic pulmonary edema. Our patient clinically improved with diuretic as well as with the anti-inflammatory effect of steroids. Thus we propose the diagnosis of pulmonary edema due to G-CSF induced capillary leak.

REFERENCES:

(1) Arimura K, et al. Acute Lung Injury in a healthy donor during mobilization of peripheral blood stem cells using G-CSF factor alone. Haematologica. 2005 Mar;90(3):ECR10.

(2) Azevedo, AM et al. Life-treatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogenic transplantation. Bone Marrow Transplantation. 2001; 28:311-312.

(3) Kitamura S, et al. A risk of pulmonary edema associated with G-CSF pretreatment. Masui 1997;46:946-950.

(4) Murray and Nadel. Textbook of Respiratory Medicine, 3rd ed, Saunders, Philadelphia, 2000.p.465

DISCLOSURE: Courtney Lucado, None.

Courtney S. Lucado MD * Kevin Cooper MD VCU-MCV Campus, Richmond, VA

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Lasix
Home Contact Resources Exchange Links ebay